Screener
MBX Biosciences, Inc. MBX Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by MBX Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210593
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Proceeds from exercise of common stock options | 2,442 | 4 |
| Payments related to offering costs | (378) | — |
| Net cash provided by financing activities | 87,435 | 4 |
| Net decrease in cash and cash equivalents | (29,870) | (19,448) |
| Cash, cash equivalents and restricted cash, beginning of period | 75,289 | 49,351 |
| Cash, cash equivalents and restricted cash, end of period | $45,419 | $29,903 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Vesting of early exercised stock options | $2 | $19 |
Item 1. Financial Statements.
FAQ
- What is MBX Biosciences, Inc.'s net change in cash?
- MBX Biosciences, Inc. (MBX) reported net change in cash of -$29.87M in Q1 2026.
- How has MBX Biosciences, Inc.'s net change in cash changed year-over-year?
- MBX Biosciences, Inc.'s net change in cash decreased by 53.6% year-over-year, from -$19.45M to -$29.87M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about MBX Biosciences, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude